Please login to the form below

Not currently logged in
Email:
Password:

Eisai sets up new pharmaceutical marketing subsidiary in Belgium

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Eisai SA/NV is owned by Eisai Europe and will serve as the regional sales centre for Benelux countries, the sixth largest market in the EU. The subsidiary will begin marketing activities in the region, focusing on the anti-epileptic drugs Zonegran (zonisamide) and Inovelon (rufinamide). It will also start to market the non-opioid severe chronic infused pain drug Prialt (ziconotide), while also co-promoting Alzheimer's disease treatment Aricept (donepezil) in Belgium and Luxembourg with its partner, Pfizer.

Eisai says it will further expand its business operations across the EU and will undertake independent marketing activities by using its own sales and marketing personnel, tailored for each county.

Eisai SA/NV is Eisai's ninth marketing subsidiary in the EU region, bringing the total number of countries where Eisai has sales and marketing operations through its own distribution channels to 17. These include the UK, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands and Luxembourg.



28th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics